| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 365 (9472), 1687-1717, 2005 | 7748 | 2005 |
| Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 366 (9503), 2087-2106, 2005 | 6161 | 2005 |
| Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ... Annals of oncology 24 (9), 2206-2223, 2013 | 4301 | 2013 |
| Tamoxifen for early breast cancer: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 351 (9114), 1451-1467, 1998 | 3967 | 1998 |
| Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer A Howell, J Cuzick, M Baum, A Buzdar, M Dowsett, JF Forbes, ... Lancet 365 (9453), 60-62, 2005 | 2959 | 2005 |
| Genome-wide association study identifies novel breast cancer susceptibility loci DF Easton, KA Pooley, AM Dunning, PDP Pharoah, D Thompson, ... Nature 447 (7148), 1087-1093, 2007 | 2779 | 2007 |
| Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial AW Bradbury, CV Ruckley, FGR Fowkes, JF Forbes, I Gillespie, DJ Adam Lancet 366 (9501), 1925-1934, 2005 | 2451 | 2005 |
| Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial C Davies, H Pan, J Godwin, R Gray, R Arriagada, V Raina, M Abraham, ... The Lancet 381 (9869), 805-816, 2013 | 2444 | 2013 |
| Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ... Annals of oncology 26 (8), 1533-1546, 2015 | 2225 | 2015 |
| Polychemotherapy for early breast cancer: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 352 (9132), 930-942, 1998 | 2158 | 1998 |
| Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC … A The The Lancet 359 (9324), 2131-2139, 2002 | 2094 | 2002 |
| A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer Breast International Group (BIG) 1-98 Collaborative Group New England Journal of Medicine 353 (26), 2747-2757, 2005 | 1965 | 2005 |
| Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 A Goldhirsch, JN Ingle, RD Gelber, AS Coates, B Thürlimann, HJ Senn Annals of oncology 20 (8), 1319-1329, 2009 | 1953 | 2009 |
| Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women … P McGale, C Taylor, C Correa, D Cutter, F Duane, M Ewertz, R Gray, ... Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews …, 2014 | 1860* | 2014 |
| Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 386 (10001), 1341-1352, 2015 | 1277 | 2015 |
| Overview of the main outcomes in breast-cancer prevention trials J Cuzick, T Powles, U Veronesi, J Forbes, R Edwards, S Ashley, P Boyle The Lancet 361 (9354), 296-300, 2003 | 1249 | 2003 |
| Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 AS Coates, A Keshaviah, B Thürlimann, H Mouridsen, L Mauriac, ... Journal of clinical oncology 25 (5), 486-492, 2007 | 1149 | 2007 |
| Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial J Cuzick, I Sestak, M Baum, A Buzdar, A Howell, M Dowsett, JF Forbes The lancet oncology 11 (12), 1135-1141, 2010 | 1137 | 2010 |
| Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial T Arimidex The lancet oncology 9 (1), 45-53, 2008 | 1099 | 2008 |
| Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial RC Coombes, LS Kilburn, CF Snowdon, R Paridaens, RE Coleman, ... The Lancet 369 (9561), 559-570, 2007 | 1092 | 2007 |
